

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-18 (Canceled).

19. (Currently amended) A kit for inducing tolerance to a graft comprising:
an anti-CD2 antibody or an antigen-binding fragment thereof in a
pharmaceutically acceptable carrier;
an immunosuppressive agent; and
instructions to administer the anti-CD2 antibody or antigen-binding fragment
thereof and to administer a short course of the immunosuppressive agent at a high dose to
a human subject to induce tolerance in the subject.
20. (Previously presented) The kit of claim 19, wherein the anti-CD2 antibody is
monoclonal.
21. (Previously presented) The kit of claim 19, wherein the antibody or antigen
binding fragment comprises BTI-322.
22. (Previously presented) The kit of claim 19, wherein the anti-CD2 antibody binds
an epitope also recognized by BTI-322.
23. (Previously presented) The kit of claim 19 wherein the immunosuppressive agent
is selected from the group consisting of cyclosporine, FK-506, and rapamycin.

24. (Previously presented) The kit of claim 23, wherein the immunosuppressive agent is cyclosporine.
25. (Previously presented) The kit of claim 24, wherein the high dose of cyclosporine is at least 10 mg/kg/day.
26. (Previously presented) The kit of claim 25, wherein the high dose of cyclosporine is at least 15 mg/kg/day.
27. (Previously presented) The kit of claim 26, wherein the high dose of cyclosporine is an amount which results in blood levels of at least 500 ng/ml of cyclosporine.
28. (Previously presented) The kit of claim 27, wherein the high dose of cyclosporine is an amount which results in blood levels of at least 1000 ng/ml of cyclosporine.
29. (Previously presented) The kit of claim 19, wherein the short course is less than 12 days.
30. (Previously presented) The kit of claim 19, wherein the short course is about 8 to 12 days.
31. (Previously presented) The kit of claim 19, wherein the short course is about 10 days.
32. (Currently amended) The kit of claim 19, wherein the instructions provide that the short course administration of the immunosuppressive agent is administered prior to introducing a graft into a recipient ~~mammal~~ human.

33. (Currently amended) The kit of claim 19, wherein the instructions provide that the short course administration of the immunosuppressive agent is administered at about the time the graft is introduced into a recipient ~~mammal~~ human.

34. (Currently amended) The kit of claim 19, wherein the instructions provide that the short course administration of the immunosuppressive agent is administered after the time the graft is introduced into a recipient ~~mammal~~ human.

35. (Currently amended) A kit for inducing tolerance to a graft comprising:
an anti-CD2 antibody comprising BTI-322 or an antigen-binding fragment thereof
in a pharmaceutically acceptable carrier;
an immunosuppressive agent; and
instructions to administer the anti-CD2 antibody or antigen-binding fragment thereof to a human subject and to administer a short course of the immunosuppressive agent at a high dose to the subject.

36. (Currently amended) A kit for inducing tolerance to a graft comprising:
an anti-CD2 antibody or an antigen-binding fragment wherein the anti-CD2 antibody or antigen-binding fragment thereof binds an epitope also recognized by BTI-322 thereof in a pharmaceutically acceptable carrier;
an immunosuppressive agent; and
instructions to administer the anti-CD2 antibody or antigen-binding fragment thereof to a human subject and to administer a short course of the immunosuppressive agent at a high dose to the subject.